Radio guided surgery in neuroendocrine tumours using 68Ga-labeled somatostatin analogs – a pilot study. Abstract #169

Introduction: Radioguided surgery (RGS) is an intraoperative localizing technique for the detection of cancer tissue using tumor-specific radionuclides.
Aim(s): To test the feasibility of doing RGS using short-lived positron emitters 68Ga labeled with somatostatin receptor analogs.
Materials and methods: 68Ga -SMS-R PET/CT imaging was performed preoperatively in 9 patients with neuroendocrine tumors. Statistical analyses was performed to find out the correlation between the pathological size of the tumor lesions and the maximum standardized uptake value (SUVmax) on PET/CT as well as the target/non-target ratio (T/NT) of gamma probe counts.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Daniel Kaemmerer

To read results and conclusion, please login ...

Further abstracts you may be interested in

#13 Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic carcinoma
Introduction: Pancreatic endocrine tumors (pNETs) are rare but are among the most common neuroendocrine neoplasms of the abdomen. At diagnosis, many of them are already advanced and difficult to treat.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Daniel Kaemmerer
#14 Radioguided surgery in NET: First impression with Ga-68 labeled somatostatin analogues
Introduction: Neuroendocrine tumors (NET) constitute a heterogenous group of neoplasms. The development of Gallium-68-labeled somatostatin analogues, such as DOTA-NOC or DOTA-TOC, PET/CT have dramatically improved the diagnosis of neuroendocrine tumors. Surgery remains the treatment of choice for localized disease as well as metastatic disease. The aims of surgery are: improvement of symptoms, reduction of tumor mass / burden and to give better quality of life to patients. Recurrent laparotomies often lead to multiple adhesions and altered anatomy. So it is increasingly difficult for imaging physicians and surgeons to separate non-malignant from malignant tissue.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Daniel Kaemmerer
#26 Molecular imaging of gastroenteropancreatic neuroendocrine tumours with Ga-68 DOTANOC PET/CT and correlation with an immunhistochemical quantification of somatostatin receptors using novel monoclonal and polyclonal antibodies
Introduction: Receptor PET/CT with somatostatin analogues marked with Gallium-68 (SMS-R-PET/CT) is currently the golden standard in diagnosing gastroenteropancreatic neuroendocrine tumors (GEP-NET), which are known for an overexpression of somatostatin receptors (SSTRs).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Daniel Kaemmerer
#27 Combined treatment of rapidly progressing neuroendocrine tumors by transcatheter arterial chemoembolisation of the liver and peptide-receptor radiotherapy is save and effective. Report of thirty consecutive patients
Introduction: Patients with rapidly progressing neuroendocrine tumors presenting with high tumor load and/or severe clinical syndromes are clinically challenging and with limited life expectany. Peptide receptor radiotherapy (PRRT) and transcatheter arterial chemoembolization (TACE) have demonstrated efficacy in the treatment of neuroendocrine tumors. However, there are no reports that both therapies have been applied in combination.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Dieter Hörsch
Keywords: PRRT, TACE
#56 Somatostatinreceptor scintigraphy with Tc-99m-tektrotyd in patients with neuroendocrine tumors: correlation with immunohistochemistry
Introduction: Somatostatin receptor scintigraphy (STRS) with Tc-99m-tektrotyd has been used in the past few years for diagnosis and staging of neuroendocrine tumors (NETs). A number of clinicopathologic criteria proved to be useful predictors of malignant behavior of these tumors. Immunohistochemical markers for NETs include cell proliferation (Ki-67 index) and neuroendocrine markers such as chromogranin A (CgA) and synaptophysin.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Margarida Rodrigues